- Home
- FPAY vs CANF Comparison
FPAY vs CANF Comparison
Compare FPAY & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FPAY
- CANF
- Stock Information
- Founded
- FPAY 2003
- CANF 1994
- Country
- FPAY United States
- CANF Israel
- Employees
- FPAY N/A
- CANF N/A
- Industry
- FPAY Diversified Commercial Services
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- FPAY Consumer Discretionary
- CANF Health Care
- Exchange
- FPAY Nasdaq
- CANF Nasdaq
- Market Cap
- FPAY N/A
- CANF 7.9M
- IPO Year
- FPAY N/A
- CANF N/A
- Fundamental
- Price
- FPAY $1.28
- CANF $1.15
- Analyst Decision
- FPAY Strong Buy
- CANF Strong Buy
- Analyst Count
- FPAY 2
- CANF 2
- Target Price
- FPAY $3.25
- CANF $14.00
- AVG Volume (30 Days)
- FPAY 55.0K
- CANF 420.2K
- Earning Date
- FPAY 04-23-2025
- CANF 05-06-2025
- Dividend Yield
- FPAY N/A
- CANF N/A
- EPS Growth
- FPAY N/A
- CANF N/A
- EPS
- FPAY N/A
- CANF N/A
- Revenue
- FPAY $139,800,732.00
- CANF $674,000.00
- Revenue This Year
- FPAY $12.05
- CANF $461.72
- Revenue Next Year
- FPAY N/A
- CANF N/A
- P/E Ratio
- FPAY N/A
- CANF N/A
- Revenue Growth
- FPAY 19.51
- CANF N/A
- 52 Week Low
- FPAY $0.97
- CANF $1.22
- 52 Week High
- FPAY $2.37
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- FPAY 51.38
- CANF 36.96
- Support Level
- FPAY $0.99
- CANF $1.13
- Resistance Level
- FPAY $1.44
- CANF $1.27
- Average True Range (ATR)
- FPAY 0.08
- CANF 0.12
- MACD
- FPAY 0.03
- CANF -0.02
- Stochastic Oscillator
- FPAY 72.97
- CANF 2.90
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).